Table 2.
Treatments | Total free amino acids (mg g−1 FW) | Proline content (µmol g--1 FW) | P5CS activity (nmol NADPH oxidised min−1 mg−1 protein) | ProDH activity (nmol NADH formed min-1 mg−1 protein) |
---|---|---|---|---|
Control | 6.9 ± 0.301d | 0.329 ± 0.045e | 30.4 ± 1.37d | 170.0 ± 8.92a |
NO | 7.4 ± 0.333cd | 0.317 ± 0.033e | 29.5 ± 1.84d | 173.6 ± 7.33a |
ABA | 7.0 ± 0.300d | 0.321 ± 0.042e | 29.1 ± 1.67d | 170.7 ± 7.77a |
PEG | 12.7 ± 0.533a | 0.452 ± 0.040a | 48.8 ± 1.61a | 121.3 ± 6.45e |
PEG + NO | 8.2 ± 0.411c | 0.401 ± 0.029c | 35.2 ± 1.46c | 158.3 ± 7.25b |
PEG + NO + ABA | 8.8 ± 0.412c | 0.361 ± 0.035d | 39.6 ± 1.33b | 150.2 ± 7.17c |
PEG + ABA | 9.6 ± 0.431b | 0.433 ± 0.042b | 41.1 ± 1.35b | 139.4 ± 5.83d |
Values are mean ± S.E. of three independent experiments, each including four biological replicates. Different letters represent significant difference between treatments, where “a” corresponds to the highest value and “d” or “e” to the lowest value.